Grant

Apply to Internal Competition // Limit: 3 // Available: 3

The submission of this funding program is coordinated by RSD with the assistance of the University of Arizona Foundation. For more information, please contact Selena Valencia-Salazar. 

The mission of The G. Harold and Leila Y. Mathers Foundation is to advance knowledge in the life sciences by sponsoring scientific research that will benefit mankind. The foundation’s grants program seeks to support basic science, ideally with potential translational applications. Immunology, microbiome, genomics, structural biology, cellular physiology, neuroscience, etc., are some noteworthy examples of current research support.

For many years the Foundation has enjoyed special recognition in the research community for supporting “basic” scientific research, realizing that true transformative breakthroughs usually occur after a thorough understanding of the fundamental mechanisms underlying natural phenomena. More recently, and with the advent of newer investigative methodologies, technology, and tools, the Foundation now embraces innovative translational research proposals.

The grant duration must be three years. The budget should be reasonable based on the aims of the project. Indirect costs may not exceed 10%. Preliminary Budgets are required during the LOI phase. A detailed budget justification is not required until the proposal phase. The Foundation’s grant award is not intended to be utilized for purchasing capital equipment (“bricks-and-mortar”) for the lab and is intended only to support the actual investigation. The Foundation assumes and expects that capital equipment must be provided by the research institution or university.

Application Guidance:

• Grant budgets cannot exceed $600-750K
• The Foundation primarily supports basic science, ideally with potential translational applications.
• Immunology, microbiome, genomics, structural biology, cellular physiology, neuroscience, etc., are some noteworthy examples of current research support.
• Covid-19-related research projects (aims or sub-aims) will not be considered for support.
• Medical imaging technology-related projects and/or electrical engineering technology development projects will not be considered for support.
• Plant Biology Research, Oceanography, Space Exploration. and Global warming-related research will not be considered for support.
• As technology continues to advance, it is apparent that investigations in the area of basic science and translational research may become more and more reliant on collaborative, interdisciplinary projects. It is important to note that any interdisciplinary project proposals may require additional information regarding the collaborator(s)’ achievements and relevant expertise.
• Feedback for declined LOI Requests will not be provided; LOIs or Formal Proposals that have been declined should not be resubmitted at a later date for consideration.
• Renewal applications for the same or related research will not be accorded priority consideration. It is strongly advised that any re-application for grant renewal consider a new direction based on prior research or emphasize some new potential translational aspects and not merely an extension of previously funded research.
• Requests for funding previously federally supported research and/or applications pending federal approval will not be accorded priority consideration.
• Requests for support of clinical trials or drug discovery will not be approved. The Foundation will not support projects which we consider pre-clinical drug development.Spring 2025 Cycle Deadlines: 

Nominations and Portal Registration due date: February 28, 2025 (Friday, 8 PM EST (5 PM PST)

Due date for LOI applications: March 14, 2025 (Friday, 8 PM EST (5 PM PST)
Applicants are notified of proposal invitation or LOI rejection within 30 days of the due date.

Due date for invited formal proposals: May 23, 2025 (Friday, 8 PM EST (5 PM PST)
Applicants are notified of proposal approval or rejection within 75 days of the due date.

Limit: 1 // Available: 0

M. Herbst-Kralovetz (Cancer Center)

The Mary Kay Ash Foundation®, a funding source for cancer research, is currently accepting applications for innovative grants for translational research of cancers affecting women, including but not limited to breast, cervical, endometrial, ovarian, uterine or cancers predominantly affecting women. 

Award Amount

The grant period is two years beginning September 1, 2025 – September 1, 2027*. Contracts are distributed to the final awardees in early June. 

Eligibility 

• The Principal Investigator must be a full-time assistant professor or higher at the time of application submission and commit a minimum 5% effort. Pending future appointments will not be honored.
• U.S. citizenship is not required.
• One Co-PI is permitted and must meet the same eligibility requirements as the PI. International Co-PIs are permitted with the caveat that all funds will be designated to the U.S.-based university. Post-doc contributors must be listed as co-investigators, not PIs.

Budget

• The total budget over two years may not exceed $100,000 (combined indirect/direct costs).
• The budget should follow the NIH format for a two-year grant ($50,000/year) and include justification.
• The NIH salary cap of $199.300 must be followed
• Indirect costs must not exceed 15% of direct costs .

Allowable Activities and Expenses

• Animal studies are allowed. However, researchers will need to indicate how their studies would impact patient care in the future should their research be successful.

• Equipment and travel costs must be justified

   

Application Requirements

A complete application must include the following:

• Research Description (6 pages max)
• Literature References Cited (2 pages max)
• Letters of Collaboration/Letters of Support (3 pages max)
• Current Financial Support (2 pages max)
• NIH-format Budget & Justification
• NIH-format Bio sketch or equivalent (5 pages max)
• If a co-PI or additional collaborators are included in your research team, please provide a brief resume for each.
• Preliminary data is not required, however it is helpful to include if available

Limit: 1 // Available: 0

R. Shroff (Medicine)

Only one application per institution (normally identified by having a unique UEI or NIH IPF number) is allowed.

The NCI National Clinical Trials Network (NCTN) was established for the conduct of large-scale, national, oncology treatment and advanced imaging clinical trials in an era of precision medicine.

Recent advances in deciphering the cancer genome, along with the emergence of successful targeted agents, immunotherapies, and cellular therapies, have fundamentally changed our approach to cancer treatment and have introduced new challenges to performing clinical trials. Due to the low incidence of certain molecular abnormalities, the development of targeted therapies often requires an infrastructure for the conduct of clinical trials that can screen large numbers of patients with the same or different cancer type to identify those patients whose tumors contain the distinct molecular targets of the therapies being tested. Immunotherapeutic approaches also present a similar challenge in that not all tumor types respond to this approach, and selecting the cancer types most likely to respond is critical for success.

The NCTN's integrated and collaborative network infrastructure has allowed the Program to meet the challenges of evaluating emerging therapies within its broad investigator base drawn from NCI-designated Cancer Centers, the NCI Community Oncology Research Program (NCORP), Minority/Underserved NCORPs, and other academic and community hospitals and private practitioners across the U.S. and internationally. The primary focus of the NCTN is the conduct of multi-center, late-phase, clinical treatment trials (i.e., randomized phase 2 and phase 3 trials) and investigation of new advanced imaging techniques; however, appropriate preliminary studies needed for development of potential definitive trials, especially umbrella/basket trials and rare tumor trials oriented to discovery, are also conducted when an extensive, national patient catchment area is required. With its state-of-the-art clinical trials infrastructure, the NCTN can implement and completes trials rapidly. The NCTN has streamlined trial registration, data management, and tumor banking processes. It has a Cancer Trials Support Unit (CTSU) to provide online access to all necessary study materials and a Central Institutional Review Board (CIRB) to make ethics review easier and less redundant across the country. The NCTN also has appeal for industry partners such as biotechnology and pharmaceutical companies that collaborate on NCTN trials, including precision medicine trials harnessing next generation DNA and RNA sequencing methods to inform treatment choices. NCTN's resources are ideal for screening large numbers of patients to identify patients whose tumors exhibit the molecular features that may be responsive to new, targeted treatments and/or immunotherapy approaches. In addition, biospecimens collected from patients on NCTN trials are available to help determine the underlying biological reasons for response and resistance to therapy.

The NCTN also promotes the evaluation of multi-modality treatments, including surgery and radiotherapy in combination with novel agents, and has a commitment to the conduct of trials in special populations (e.g., children, adolescents, young adults, and underserved populations) as well as in rare tumor types. This focus allows the NCTN Program to complement, rather than duplicate, research conducted by the private sector. Annual accrual to NCTN trials has remained in the 17,500 to 22,000 patient range in mostly large phase 2 and phase 3 trials, but with a larger number of patients screened on study to determine whether they might benefit from the therapy under evaluation.

Each of the key components of the NCTN Program is described briefly below.

• Network Group Operations Centers: The Operations Centers provide scientific leadership for developing and implementing multi-disciplinary, multi-institutional trials in a range of diseases and special populations with specific scientific strategy and goals. The Operations Centers' scientific goals may include strategic innovation in advanced technology for specific research areas (e.g., advanced imaging methods/agents, radiotherapy) and the testing of innovative concepts and tools in prospective, multi-institutional clinical trials. Operations Centers are responsible for trial operations including timely protocol development and management, compliance with the Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP) regulatory and patient protection requirements, audits, training, quality assurance, and site support. The Operations Centers are expected to be closely integrated with their corresponding Statistics and Data Management Center in all aspects of trial operations through jointly developed policies and procedures for clinical trial development and conduct. The Operations Centers are also responsible for Network Group administration, including financial management, monitoring of member institution/site performance, coordination of biospecimen collection from patients on clinical trials, and adherence to all applicable NIH/NCI policies and regulations. Network Group Operations Centers may also provide trial operations for NCI Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis (NCI/DCTD, approved, multi-center phase 2 and phase 3 trials originating outside the Network Groups in special situations.
• Network Group Statistics and Data Management Centers: These Centers are responsible for providing the statistical expertise required to ensure effective scientific design and conduct of clinical trials as well as leadership in innovation in statistical methodology. These Centers are also responsible for data management, data analysis, and statistical analysis for NCTN trials led by their affiliated Network Group Operations Center as well as for translational and other ancillary studies associated with the trials.
• Network Group Integrated Translational Science Centers - These awards provide support for leadership and expertise to facilitate incorporating translational science into Network Group clinical trials.
• Network Lead Academic Participating Sites: These academic institutions/sites provide scientific leadership in development and conduct of clinical trials in association with one or more adult U.S. Network Groups as well as substantial accrual to clinical trials conducted across the entire NCTN.
• Network Radiotherapy and Imaging Core Services Center: This institution/organization provides scientific and technical expertise for incorporation of appropriate, integrated quality assurance/control and image data management for applicable clinical trials conducted by the NCTN that require specialized quality assurance/control or imaging data management and/or assessment for radiotherapy and imaging interventions. In addition, the Center may also provide similar services for other approved NCI-supported clinical trials network programs (e.g., NCI/DCTD/CTEP early phase clinical trial network program and the NCI Division of Cancer Prevention (NCI/DCP) NCI Community Oncology Research Program (NCORP).
• Canadian Collaborating Clinical Trials Network: This Canadian organization is a non-profit clinical trials organization capable of being a full partner with the U.S. Network in the conduct of large-scale, multi-site clinical trials that have relevance for U.S. cancer patient populations. Incorporation of a Canadian Clinical Trials Network as a collaborating partner brings an additional advantage as U.S. Network Groups are anticipated to have Canadian member sites. A Canadian network can help reduce duplicative regulatory staff at U.S. NCTN Group Operations Centers.

Interactions with Other NCI-supported Programs. In addition to the six key components of the NCTN that are described above that are directly funded by the NCTN Program, other NCI grant and contract-supported Programs and their awardees as well as NCI Advisory Committees have important supporting roles in carrying out the research objectives of the NCTN Program. Thus, the NCTN awardees are expected to interact as appropriate with such entities/programs as the NCI Clinical Trials Tumor Banks, the NCI Community Oncology Research Program (NCORP) and Minority/Underserved NCORPs, the NCI Cancer Trials Support Unit, the pediatric and adult NCI Central Institutional Review Boards, and NCI Advisory and Scientific Committees, including the NCI Scientific Steering Committees.

Main Research Objectives and Requirements of this NOFO

The Network Lead Academic Participating Site application must address the following 2 required functional components related to clinical treatment trials and advanced imaging trials for adult cancer patients only:

Clinical Trial Program - This functional component encompasses the LAPS scientific leadership in helping to develop and conduct clinical trials in association with one or more Network Groups, including the LAPS support of NCTN initiatives and mentorship of junior investigators.

Site Accrual Program This functional component provides robust accrual to NCTN trials across the Network, including accrual to rare cancers and accrual from special populations (e.g., minority and underserved communities, adolescents and young adults), as well as timely activation of trials and good clinical trial stewardship.

B. James  (Department of Medicine)

UA may submit one proposal.

Through project-based funding, the program supports public engagement with, and access to, various forms of art across the nation, the creation of art, learning in the arts at all stages of life, and the integration of the arts into the fabric of community life. We fund arts projects in the following disciplines: Artist Communities, Arts Education, Dance, Design, Folk & Traditional Arts, Literary Arts, Local Arts Agencies, Media Arts, Museums, Music, Musical Theater, Opera, Presenting & Multidisciplinary Arts, Theater, and Visual Arts.

A project may consist of one or more specific events or activities; it may be a new initiative or part of your organization’s regular season or activities. Organizations that undertake a single short-term program in a year could apply for that event, or they could identify certain components (such as the presentation of a particular artist and the associated activities) as their project. Organizations may apply for any or all phases of a project, from its planning through its implementation. A project should not encompass all of an organization’s activities or costs in a given year.

Additional submission information:

• An organization may submit only one application under these FY 2024 Grants for Arts Projects guidelines (i.e., one application per calendar year).
• All Artist Communities and Design applicants must apply at the February 9, 2023, deadline.
• An organization may not apply to both the Challenge America category and the Grants for Arts Projects category in the same calendar year. UA is not eligible to apply to the Challenge America, due an active award.
• An organization may apply to other NEA funding opportunities, including Our Town, in addition to Grants for Arts Projects. If you submit applications to other opportunities, each request must be for a distinctly different project or a distinctly different phase of the same project, with a different period of performance and costs.

   

Exceptions to the one-application rule are made only for:

• Parent (and Related) Organizations
  A parent organization that comprises separately identifiable and independent components (e.g., a university campus that has a presenting organization and a radio station) may submit an application for each such component. In addition, a parent organization also may submit one application on its own behalf for a project that is different from any project submitted in an application by its independent component(s).

• Applicants to the Media Arts discipline at the July 6, 2023, deadline
  An organization of any artistic discipline may submit one additional application in the Grants for Arts Projects category through the Media Arts discipline at the July 6, 2023, deadline. The additional application must be for a distinctly different project and must align with certain programmatic requirements described here: Additional Applications in Media Arts.

   

Areas of particular interest:

• Elevate artists as integral and essential to a healthy and vibrant society.
• Celebrate the nation’s creativity and/or cultural heritage.
• Facilitate cross-sector collaborations that center the arts at the intersection of other disciplines, sectors, and industries.
• Contribute to healthy and thriving local, regional, state-wide, and national arts ecosystems and arts infrastructures.
• Invest in organizational capacity-building and leadership development for arts organizations, arts workers, and artists.
• Build arts organizations’ capacity to serve a broad public through digital or emergent technology and/or support tech-centered creative practices across all artistic disciplines and forms.
• Originate from or are in collaboration with the following constituencies encouraged by White House Executive Orders:
  • Historically Black Colleges and Universities,
  • Tribal Colleges and Universities,
  • American Indian and Alaska Native tribes,
  • Predominantly Black Institutions,
  • Hispanic Serving Institutions,
  • Asian American and Pacific Islander communities, and
  • Organizations that support the independence and lifelong inclusion of people with disabilities.

No applicants // Limit: 1 // Tickets Available: 1 

The purpose of this program is to provide support to entities providing health care, health care providers associations, and Federally Qualified Health Centers (FQHCs), taking into consideration the needs of rural and medically underserved communities, to establish, enhance, or expand evidence informed or evidenced-based programs or protocols to promote resilience, mental health, and wellness among their providers, other personnel, and members, collectively known as the “Health Workforce.”

No applicants.

No applicants // Limit: 1 // Tickets Available: 1 

The purpose of this program is to provide tailored training and technical assistance (TA) to Health Resources and Services Administration’s (HRSA’s) health workforce resiliency grant recipients to establish, enhance and expand the capacity and infrastructure to rapidly deploy evidence-informed or evidence-based innovative strategies that promote mental and behavioral health, prevent suicide, as well as reduce burnout and substance use among providers, health care professionals, health care students, residents, professionals, paraprofessionals, trainees, public safety officers and employers of such individuals, collectively known as the “Health Workforce” for the purpose of this NOFO. These health workforce resiliency grant recipients have a special focus on the Health Workforce in rural and medically underserved communities.

No applicants.

No applicants // Limit: 1 // Tickets Available: 1 

The vision of the NSF INCLUDES Big Idea is to catalyze the STEM enterprise to work collaboratively for inclusive change, resulting in a STEM workforce that reflects the population of the Nation. More specifically, NSF INCLUDES seeks to broaden participation in STEM fields through a National Network that will inspire collaborative efforts aimed at increasing the active participation of those who have been historically underrepresented and underserved in STEM.

K. John

No applicants // Limit: 1 // Tickets Available: 1 

The U.S. Embassy Singapore at the U.S. Department of State (DOS) announces this Notice of Funding Opportunity (NOFO) to support cybersecurity capacity-building efforts primarily for the Southeast Asian region, including under existing programs such as the U.S.-Singapore Cybersecurity Technical Assistance Program (CTAP) for ASEAN Countries and the U.S.-Singapore Third-Country Training Program (TCTP) as well as those under the umbrella of the ASEAN-Singapore Cybersecurity Centre of Excellence (ASCCE).

No applicants.

No applicants // Limit: 1 // Tickets Available: 1 

This notice announces the opportunity to apply for funding under the Global Reach II Program. The purpose of this initiative is to collaboratively formulate and deliver high quality solutions across the range of programming required to achieve sustainable HIV epidemic control as guided by the Office of the Global AIDS Coordinator of the U.S. State Department, emphasizing new and innovative approaches pursued jointly with HRSA and other stakeholders. An additional purpose is to assist with translating new science into programming and to mitigate the impact of forces such as global pandemics in the HIV response. Programs and activities are to span health services, structural interventions, and data use and tracking systems. Global Reach  encompasses four major categories of support: 1. HIV Direct Service Delivery 2. Human Resources for Health 3. Quality Improvement 4. Health Systems Strengthening. Global Reach II will also leverage HRSA’s broader expertise and equities on global health needs.

No applicants.

No applicants.